Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-transplant Clinical Outcome.
Hepatocellular carcinoma
Liver cancer
Locoregional therapy
Transarterial chemoembolization
Transplant
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
18
05
2020
revised:
15
09
2020
accepted:
11
10
2020
pubmed:
25
10
2020
medline:
24
6
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
Long waiting times due to ongoing organ shortage have led to increased utilization of locoregional therapies (LRTs) to bridge patients with hepatocellular carcinoma (HCC) to liver transplantation (LT). We performed this study to evaluate the impact of LRTs on post-LT outcomes. We conducted a retrospective study of patients who were transplanted for HCC at Stanford University Hospital between 2008 and 2018 (n = 302). We found that receipt of ≥5 LRTs was an independent and significant predictor of poor overall 5-year survival (58.3% vs. 83.3%; HR 2.26, p = .03), poor recurrence-free 5-year survival (51.9% vs. 80.4%; HR 2.12, p = .03), and was associated with higher rates of recurrence (25.0% vs. 7.4%, p = .001). Moreover, recurrent HCC was more likely to be the cause of death (58.3% vs. 41.7%, p = .04) in patients who received ≥5 LRTs. Also, patients who required ≥5 LRTs showed an overall lower rate of radiological complete response (46.9% vs. 97.8%, p = .001) and were more likely to have more advanced pathological stage tumors in the explant (65.6% vs. 29.6%, p < .001). In conclusion, receipt of ≥5 bridging LRTs prior to LT is associated with worse post-transplant clinical outcomes.
Identifiants
pubmed: 33098134
doi: 10.1111/ctr.14128
pmc: PMC10367045
mid: NIHMS1903023
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14128Subventions
Organisme : NCI NIH HHS
ID : K08 CA222676
Pays : United States
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Ann Surg. 2017 Sep;266(3):525-535
pubmed: 28654545
Liver Transpl. 2013 Oct;19(10):1108-18
pubmed: 23873764
HPB (Oxford). 2019 Dec;21(12):1718-1726
pubmed: 31171489
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Clin Gastroenterol Hepatol. 2017 May;15(5):767-775.e3
pubmed: 28013117
AJR Am J Roentgenol. 2017 Oct;209(4):W211-W220
pubmed: 28813195
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Liver Transpl. 2011 Aug;17(8):943-54
pubmed: 21491582
Hepatology. 2020 Dec;72(6):2051-2062
pubmed: 32157711
Int J Hepatol. 2012;2012:684802
pubmed: 22690340
JAMA Oncol. 2017 Apr 01;3(4):493-500
pubmed: 27838698
Transplant Proc. 2018 Dec;50(10):3571-3576
pubmed: 30577240
Transplantation. 2019 Apr;103(4):747-754
pubmed: 29672442
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Ann Surg. 2020 Apr;271(4):616-624
pubmed: 30870180
Cancer. 2020 May 15;126(10):2267-2278
pubmed: 32201944